Biomarkers in diabetic foot
Not Applicable
- Conditions
- Health Condition 1: E136- Other specified diabetes mellituswith other specified complications
- Registration Number
- CTRI/2021/01/030653
- Lead Sponsor
- ady Hardinge Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All new patients of any sex with 18 to 65 years of age with type 2 diabetes mellitus with diabetic foot ulcer in Lady Hardinge Medical College and associated hospitals.
Exclusion Criteria
1) Any patient who has received any antibiotics in last seven days.
2) Patients with other known site of infection.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evels of Biomarkers Procalcitonin and d-dimer among the patients of Diabetic Foot Ulcer <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: Baseline Levels at presentation <br/ ><br> <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method Grade of Diabetic Foot Ulcer and itâ??s correlation with Levels of Biomarkers.Timepoint: Baseline At presentation
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link procalcitonin and d-dimer to diabetic foot complications in E136 diabetes mellitus?
How do serum biomarkers procalcitonin and d-dimer compare to standard-of-care diagnostic methods for diabetic foot ulcers?
Can procalcitonin and d-dimer levels predict patient response to existing diabetic foot treatments in E136 cases?
What adverse events are associated with biomarker-guided management strategies for diabetic foot infections?
Are there combination therapies involving procalcitonin or d-dimer modulation for E136 diabetes mellitus with foot complications?